iStopMM

iStopMM (Iceland screens, treats or prevents multiple myeloma) is a nationwide screening study performed in Iceland

[iStopMM @iStopMM]

The #iStopMM study is a population-based screening study for MGUS, smoldering MM and MM. In total 80,743 people (54.2% of the Icelandic population >40 yrs) gave informed consent for screening.
This is the highest participation rate in a clinical study in one nation ever! #mmsm

[Sigurdur Kristinsson @sykristinsson]

I am deeply saddened by the passing of Dr Brian Durie, a visionary leader, pioneering scientist, and dear friend to me and the @iStopMM team.

He worked with us from the very beginning and coauthored all iStopMM papers.

His legacy will continue to inspire us.

[Sigurdur Kristinsson @sykristinsson]

A new publication from the @iStopMM study, published in @JAMAOnc in 2025, redefines light chain MGUS (LC-MGUS) by introducing new, age-stratified reference intervals for serum free light chains (FLC). 📊🩸 #iStopMM #MultipleMyeloma #mmsm

[Kenar Jhaveri @kdjhaveri]

New Definition of Light Chain Monoclonal Gammopathy of Undetermined Significance | Nephrology | JAMA Oncology | JAMA Network https://t.co/EzHGOiN5YC

[Þórir Long @thorirlong]

🧵1/ Our paper is out! A new study from the iStopMM team in @JAMAOnc shows how revising free light chain (FLC) reference intervals can reduce false positives for light chain MGUS (LC-MGUS). Let’s break it down 👇
https://t.co/yBUwTZtKru

[Samer Al Hadidi, MD,MS,FACP @HadidiSamer]

New Definition of Light Chain Monoclonal Gammopathy of Undetermined Significance @iStopMM

@JAMAOnc #mmsm

https://t.co/iAf93uLzKQ

Important data coming to support need for new ranges of normal free light chains based on eGFR👇

[Sigurdur Kristinsson @sykristinsson]

Thank you all for participating in our survey!

It is still open for those that have not completed it yet. Your input is of great importance!

Take part & help spread the word: https://t.co/q2qMe6KPHY

[Sigurdur Kristinsson @sykristinsson]

The 21st publication from the @iStopMM study, published in Archives of Dermatological Research in 2024, investigates the potential association between monoclonal gammopathies (MGUS, SMM, MM) and alopecia (hair loss). 📊🔬 #iStopMM #dermatology

[OncoDaily @oncodaily]

Calling all myeloma experts, nurses, and patients - @sykristinsson
@iStopMM @IMFmyeloma

https://t.co/ACV4Eqc4KM

#IMF #MGUS #Cancer #OncoDaily #Medicine #Oncology #MedEd #MedX #MedNews

[Sigurdur Kristinsson @sykristinsson]

@MTomasson @iStopMM @IMFmyeloma That is the point. Should not represent current practice. We aim to be practice changing ;)

[Hira Mian @HiraSMian]

I hear all the cool 😎 ppl are filling out this survey, please fill
and retweet! @MyelomaCanada @rajshekharucms @JoshuaRichterMD @HadidiSamer @SurbhiSidanaMD @bdermanmd @RahulBanerjeeMD @sykristinsson

[Rahul Banerjee, MD, FACP @RahulBanerjeeMD]

There’s no right answer, so tell us yours!

Great to see @iStopMM group at it again - patients, nurses, APPs, and physicians can fill out easy survey (written in patient-friendly language) about what % #MMsm risk and pt scenarios might prompt BMBx.

https://t.co/9bn6QfWiMu

[Saad Z. Usmani MD MBA FASCO 🇺🇸🇵🇰 @szusmani]

This right here #mmsm peeps! 👇🏽😊

[Sigurdur Kristinsson @sykristinsson]

Calling all myeloma experts, nurses, and patients!🩺🧬
The @iStopMM team & @IMFmyeloma need your input:
When should we do a bone marrow biopsy in MGUS?

📋 Anonymous 🕒 10 min 💡 impactful

Take part & help spread the word: https://t.co/q2qMe6KPHY

#Myeloma #mmsm

[Sigurdur Kristinsson @sykristinsson]

The 20th publication from the @iStopMM study, a collaborative effort published in @NatureComms in 2024, explores genetic factors underlying multiple myeloma (MM) risk through a genome-wide association study (GWAS). 🧬🔍 #iStopMM #mmsm @IMFmyeloma

[Sigurdur Kristinsson @sykristinsson]

The 18th publication from the @iStopMM study, published in @AnnalsofIM in 2024, presents a multivariable model to predict the need for bone marrow (BM) sampling in individuals with monoclonal gammopathy of undetermined significance (MGUS). 🩸📈 #iStopMM #MGUS @IMFmyeloma

[Sigurdur Kristinsson @sykristinsson]

The 17th publication from the @iStopMM study, published in @Haematologica in 2024, investigates the association between prior cancer and the risk of developing MGUS, as well as MGUS progression. 🩸📊 #iStopMM #MultipleMyeloma #mmsm @SaemundurMD

[Sigurdur Kristinsson @sykristinsson]

The 16th publication from the @iStopMM study, published in Clinical Chemistry in 2024, reviews the current evidence on screening for multiple myeloma (MM) and its precursors, evaluating whether screening meets established criteria for implementation🩸 #iStopMM #mmsm @SaemundurMD

[Sigurdur Kristinsson @sykristinsson]

The 15th publication from the @iStopMM study, published in @EURPUB_HSJ in 2023, investigates trends of perceived disruption in healthcare services during the COVID-19 pandemic in Iceland and its association with socio-demographic factors and pre-existing health conditions. 🏥📊

[Sigurdur Kristinsson @sykristinsson]

The 14th publication from the @iStopMM study, published in @BloodCancerJnl (2023), investigates the immunophenotypic profile of early-stage monoclonal gammopathies using high-sensitivity next-generation flow cytometry (NGF). 🩸🔬 #iStopMM #MultipleMyeloma #mmsm @IMFmyeloma

[Sigurdur Kristinsson @sykristinsson]

The 13th publication from the @iStopMM study, published in @BloodCancerJnl in 2023, presents a novel bone marrow quality index (BMQI) to assess hemodilution in bone marrow (BM) aspirates for plasma cell disorders. 🩸📊 #iStopMM #MultipleMyeloma Led by @jthorir 🧵